OVERVIEW
Reported data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response the the Neo-ALTTO trial.
STUDY DETAILS
The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
Title of Publication
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
AUTHORS
De Azambuja, E., Holmes, A.P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R.F., Untch, M., Jackisch, C., Lang, I., Smith, I. and Boyle, F., Xu, B., Barrios, C.H., Perez, E.A., Azim, H.A., Kim, S-B., Kuemmel, S. Huang, C-S., Vuylsteke, P., Hsieh, R-K., Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R.D., Eidtmann, H., and Baselga, J.
Publication Reference
The Lancet Oncology | Volume 15 | Issue 10 | Page(s) 1137-1146 | 2014
